Table 1 Demographic and clinical characteristics comparing CENO and HGSOC (pre-matching and pos-matching)

Characteristic

HGSOC

CENO

HGSOC

CENO

N(%)

N(%)

N(%)

N(%)

All

31,567

216

548

157

Year of diagnosis

2000–2001

3058 (9.7)

31 (14.4)

0.038

86 (15.7)

25 (15.9)

0.904

2002–2005

6108 (19.3)

46 (21.3)

124 (22.6)

38 (24.2)

2006–2017

22,401 (71.0)

139 (64.4)

338 (61.7)

94 (59.9)

Laterality

Bilateral

16,277 (51.6)

51 (23.6)

< 0.001

175 (31.9)

42 (26.8)

0.609

Left

5973 (18.9)

82 (38.0)

179 (32.7)

57 (36.3)

Paired site, but no information concerning laterality

3010 (9.5)

11 (5.1)

32 (5.8)

11 (7.0)

Right

6307 (20.0)

72 (33.3)

162 (29.6)

47 (29.9)

Surgery status

No surgery

3356 (10.6)

16 (7.4)

0.155

52 (9.5)

15 (9.6)

1

Surgery

28,211 (89.4)

200 (92.6)

496 (90.5)

142 (90.4)

Radiation therapy

No radiation

31,300 (99.2)

203 (94.0)

< 0.001

525 (95.8)

145 (92.4)

0.123

Radiation

267 (0.8)

13 (6.0)

23 (4.2)

12 (7.6)

Chemotherapy status

Chemotherapy

25,056 (79.4)

142 (65.7)

< 0.001

358 (65.3)

99 (63.1)

0.667

No chemotherapy/Unknown

6511 (20.6)

74 (34.3)

190 (34.7)

58 (36.9)

Number of primary tumors

1st of 2 or more primaries

2435 (7.7)

49 (22.7)

< 0.001

70 (12.8)

22 (14.0)

0.786

One primary only

29,132 (92.3)

167 (77.3)

478 (87.2)

135 (86.0)

Race

Black

2145 (6.8)

15 (6.9)

0.012

40 (7.3)

13 (8.3)

0.909

Other (American Indian/AK Native, Asian/Pacific Islander)

2505 (7.9)

29 (13.4)

73 (13.3)

20 (12.7)

White

26,917 (85.3)

172 (79.6)

435 (79.4)

124 (79.0)

Marital status at diagnosis

DSW

8665 (27.4)

52 (24.1)

0.001

152 (27.7)

40 (25.5)

0.941

Married

16,818 (53.3)

101 (46.8)

253 (46.2)

74 (47.1)

Single

4926 (15.6)

56 (25.9)

122 (22.3)

36 (22.9)

Unknown

1158 (3.7)

7 (3.2)

21 (3.8)

7 (4.5)

Median household income

< 50,000

3484 (11.0)

16 (7.4)

0.148

50 (9.1)

14 (8.9)

0.854

>=70,000

13,582 (43.0)

90 (41.7)

236 (43.1)

64 (40.8)

50,000-69,999

14,501 (45.9)

110 (50.9)

262 (47.8)

79 (50.3)

Age

<=57

11,147 (35.3)

133 (61.6)

< 0.001

304 (55.5)

88 (56.1)

0.986

>=74

6712 (21.3)

23 (10.6)

83 (15.1)

23 (14.6)

58–73

13,708 (43.4)

60 (27.8)

161 (29.4)

46 (29.3)

Grade

I/II

4476 (14.2)

102 (47.2)

< 0.001

188 (34.3)

58 (36.9)

0.606

III/IV

20,190 (64.0)

77 (35.6)

262 (47.8)

68 (43.3)

Unknown

6901 (21.9)

37 (17.1)

98 (17.9)

31 (19.7)

Seer stage

Distant

24,533 (77.7)

76 (35.2)

< 0.001

273 (49.8)

74 (47.1)

0.909

Localized

1671 (5.3)

62 (28.7)

104 (19.0)

33 (21.0)

Regional

4880 (15.5)

74 (34.3)

155 (28.3)

46 (29.3)

Unknown

483 (1.5)

4 (1.9)

16 (2.9)

4 (2.5)

Stage

I

2732 (8.7)

88 (40.7)

< 0.001

154 (28.1)

42 (26.8)

0.917

II

2243 (7.1)

34 (15.7)

70 (12.8)

23 (14.6)

III

15,381 (48.7)

43 (19.9)

157 (28.6)

42 (26.8)

IV

8980 (28.4)

34 (15.7)

103 (18.8)

33 (21.0)

Unknown

2231 (7.1)

17 (7.9)

64 (11.7)

17 (10.8)

tumor size

<=59

6635 (21.0)

34 (15.7)

< 0.001

99 (18.1)

27 (17.2)

0.782

> = 177

1387 (4.4)

23 (10.6)

33 (6.0)

13 (8.3)

60–176

11,894 (37.7)

106 (49.1)

248 (45.3)

71 (45.2)

Unknown

11,651 (36.9)

53 (24.5)

168 (30.7)

46 (29.3)

Lymph nodes status

negative

7521 (23.8)

26 (12.0)

< 0.001

91 (16.6)

26 (16.6)

0.855

positive

7042 (22.3)

94 (43.5)

176 (32.1)

54 (34.4)

Unknown

17,004 (53.9)

96 (44.4)

281 (51.3)

77 (49.0)

CA125

negative

1266 (4.0)

105 (48.6)

< 0.001

165 (30.1)

53 (33.8)

0.383

positive

19,276 (61.1)

24 (11.1)

109 (19.9)

24 (15.3)

Unknown

11,025 (34.9)

87 (40.3)

274 (50.0)

80 (51.0)